Malin Corporation

Malin Corporation Liabilities

The The Liabilities of Malin Corporation (MLC.IR) as of Sep 30, 2026 is 5.30 M EUR. In the previous year, The Liabilities was 7.10 M EUR — a change of -25.35% (lower).

Liabilities

5.30 MEUR

YoY

-25.35%

Last updated:

In 2026, Malin Corporation's total liabilities amounted to 5.30 M EUR, a -25.35% difference from the 7.10 M EUR total liabilities in the previous year.

The Malin Corporation Liabilities history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Liabilities
Date
Liabilities
Jan 1, 2017
86.60 M EUR
Jan 1, 2018
94.00 M EUR
Jan 1, 2019
92.70 M EUR
Jan 1, 2020
80.50 M EUR
Jan 1, 2021
9.30 M EUR
Jan 1, 2022
4.80 M EUR
Jan 1, 2023
7.10 M EUR
Jan 1, 2024
5.30 M EUR
The Malin Corporation Liabilities history
YEARLiabilitiesYoY
5.30 MEUR-25.35%
7.10 MEUR+47.92%
4.80 MEUR-48.39%
9.30 MEUR-88.45%
80.50 MEUR-13.16%
92.70 MEUR-1.38%
94.00 MEUR+8.55%
86.60 MEUR-8.65%
94.80 MEUR+61.22%
58.80 MEUR—
Access this data via the Eulerpool API

Malin Corporation Stock analysis

What does Malin Corporation do? Malin Corporation PLC is an Irish company that was founded in 2014. The company is a subsidiary of Elan, a company specialized in pharmaceutical development. Malin has focused its business model on identifying, supporting, and scaling startup companies. The company supports and invests in startups in the biopharmaceutical industry that focus on new and innovative therapies. Malin offers help and advice to its portfolio companies in product development and business organization. The company has invested in various areas of the biopharmaceutical industry. For example, it has supported YumaTherapeutics, a company focused on the discovery and development of novel therapeutics for infectious diseases. Malin has also provided financial support to Seres Therapeutics, which has built a pipeline of therapeutics targeting the microbiome, the collection of microorganisms living in the gut. Malin has invested in Inivata, a company specialized in the development of cancer diagnostics. Furthermore, Malin has various other companies in its investment pipeline that deal with a variety of therapeutic possibilities. This includes therapies for genetic diseases and inherited metabolic disorders, as well as applications of gene therapy and immunotherapy. Malin Corporation PLC has also developed its own products and partnerships. One of these partnerships is with Novaerus, another Irish company specialized in the development of air purification systems. Novaerus systems use a plasma-based ion system to destroy bacteria, viruses, and fungi in the air, thus preventing infections. Malin is also involved in research collaborations. One collaboration is with University College Dublin, where Malin provides financial support for research on biopharmaceutical processes. The history of Malin Corporation PLC is characterized by a strong commitment to supporting innovative companies in the biopharmaceutical industry. The company aims to promote the growth and development of startups, offering not only financial support but also advice and expertise. Malin has diversified its investments in various areas of the biopharmaceutical industry and focuses on promoting products that improve people's health and well-being. The company has also developed its own products and partnerships to bring new technologies and therapies to the market. Overall, Malin Corporation PLC is a company specialized in supporting and promoting startups in the biopharmaceutical industry. The company is committed to developing products and therapies that have the potential to improve and prolong people's lives. Malin Corporation is one of the most popular companies on Eulerpool.

Liabilities Details

Assessing Malin Corporation's Liabilities

Malin Corporation's liabilities constitute the company's financial obligations and debts owed to external parties and stakeholders. They are categorized into current liabilities, due within a year, and long-term liabilities, which are due over a longer period. A detailed assessment of these liabilities is crucial for evaluating Malin Corporation's financial stability, operational efficiency, and long-term viability.

Year-to-Year Comparison

By comparing Malin Corporation's liabilities year-over-year, investors can identify trends, shifts, and anomalies in the company’s financial positioning. A decrease in total liabilities often signals financial strengthening, while an increase might indicate enhanced investments, acquisitions, or potential financial strain.

Impact on Investments

Malin Corporation's total liabilities play a significant role in determining the company's leverage and risk profile. Investors and analysts examine this aspect meticulously to ascertain the firm’s ability to meet its financial obligations, which influences investment attractiveness and credit ratings.

Interpreting Liability Fluctuations

Shifts in Malin Corporation’s liability structure indicate changes in its financial management and strategy. A reduction in liabilities reflects efficient financial management or debt payoffs, while an increase may suggest expansion, acquisition activities, or accruing operational expenses, each carrying distinct implications for investors.

Frequently Asked Questions about Malin Corporation stock

The Liabilities of Malin Corporation is 5.30 M EUR in 2026.

The Liabilities of Malin Corporation changed from 7.10 M EUR to 5.30 M EUR, representing a -25.35% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Liabilities Malin Corporation since 2006 – with annual values, charts, and detailed analysis.

The Liabilities's EUR is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Liabilities's Malin Corporation historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Malin Corporation

All Key Metrics — Malin Corporation